Ascentage Pharma Group International (NASDAQ:AAPG) Sets New 52-Week Low – Here’s What Happened

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) reached a new 52-week low during trading on Friday . The stock traded as low as $16.48 and last traded at $16.78, with a volume of 173232 shares trading hands. The stock had previously closed at $17.05.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AAPG. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. BTIG Research reiterated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. Based on data from MarketBeat.com, Ascentage Pharma Group International has an average rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Trading Down 1.6%

The stock’s fifty day moving average is $20.22 and its 200-day moving average is $23.71. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million for the quarter. On average, research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -0.96 EPS for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Institutional investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $383,000. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International during the second quarter worth approximately $391,000. XY Capital Ltd boosted its position in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. Finally, UBS Group AG grew its holdings in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.